Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 2Advanced Renal Cell Carcinoma (RCC) 1

Interventions

Magnetic Resonance Spectroscopy 81Specimen Handling 80Cyclophosphamide 72pembrolizumab 61Nivolumab 53Radiotherapy 52fludarabine 43Cisplatin 42Biopsy 40Carboplatin 38Standard of Care 35Dexamethasone 31Radiation 30Bevacizumab 30Rituximab 29Surveys and Questionnaires 27Radiosurgery 26Doxorubicin 26Temozolomide 25Gemcitabine 25Cytarabine 25Blood Specimen Collection 25venetoclax 24Practice Guidelines as Topic 24Paclitaxel 24fludarabine phosphate 23Ipilimumab 21atezolizumab 20Vincristine 20Interviews as Topic 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Axitinib × 30 days × Clear all
NCT07630363 2026-06-05

PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting
40 enrolled
Genitourinary

Advanced Renal Cell Carcinoma (RCC)

NCT03092856 2026-06-03

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

University of Southern California

Phase 2 Active not recruiting
62 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT03172754 2026-05-22

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Fox Chase Cancer Center

Phase 1/2 Active not recruiting
98 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡